Wendy A Davis

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5128915/wendy-a-davis-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126 papers	2,662 citations	27 h-index	47 g-index
131 ext. papers	3,161 ext. citations	5.7 avg, IF	5.23 L-index

#	Paper	IF	Citations
126	The pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal weight, overweight and obese healthy male adults. *International Journal of Antimicrobial Agents*, **2021**, 106482	14.3	0
125	A prospective six-month audit of inpatient hypoglycemia in step-down general medical and geriatric wards. *International Journal of Medical Sciences*, **2021**, 18, 3744-3747	3.7	0
124	Assessment of biomarkers associated with rapid renal decline in the detection of retinopathy and its progression in type 2 diabetes: The Fremantle Diabetes Study Phase II. *Journal of Diabetes and Its Complications*, **2021**, 35, 107853	3.2	1
123	Wound healing with "spray-on" autologous skin grafting (ReCell) compared with standard care in patients with large diabetes-related foot wounds: an open-label randomised controlled trial. *International Wound Journal*, **2021**,	2.6	2
122	Knowledge of ocular complications of diabetes in community-based people with type 2 diabetes: The Fremantle Diabetes Study II. *Primary Care Diabetes*, **2021**, 15, 554-560	2.4	1
121	The association between carotid disease, arterial stiffness and diabetic retinopathy in type 2 diabetes: the Fremantle Diabetes Study Phase II. *Diabetic Medicine*, **2021**, 38, e14407	3.5	1
120	Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I. *Journal of Diabetes and Its Complications*, **2021**, 35, 107773	3.2	0
119	Community-based management of complex type 2 diabetes: adaptation of an integrated model of care in a general practice setting. *Internal Medicine Journal*, **2021**, 51, 62-68	1.6	7
118	Temporal Trends in Incident Hospitalization for Diabetes-Related Foot Ulcer in Type 2 Diabetes: The Fremantle Diabetes Study. *Diabetes Care*, **2021**, 44, 722-730	14.6	9
117	Incidence and predictors of idiopathic pulmonary fibrosis complicating Type 2 diabetes: the Fremantle Diabetes Study Phase I. *Internal Medicine Journal*, **2021**, 51, 276-279	1.6	3
116	Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the Australian National Diabetes Audit from 2013 to 2019. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2603-2613	6.7	3
115	Intra-abdominal hypertension and hypoxic respiratory failure together predict adverse outcome - A sub-analysis of a prospective cohort. *Journal of Critical Care*, **2021**, 64, 165-172	4	2
114	Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
113	The relationship between carotid disease and retinopathy in diabetes: a systematic review. *Cardiovascular Diabetology*, **2020**, 19, 54	8.7	5
112	Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
111	Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II. *Diabetic Medicine*, **2020**, 37, 1688-1695	3.5	2
110	Incidence and predictors of vision loss complicating type 2 diabetes: The Fremantle Diabetes Study Phase II. *Journal of Diabetes and Its Complications*, **2020**, 34, 107560	3.2	0

109	Influence of Renin-Angiotensin System Inhibitors on Lower-Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Care*, **2020**, 43, 2113-2120	14.6	7
108	Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II. *Clinical Endocrinology*, **2020** , 92, 373-382	3.4	2
107	Temporal Trends in Cardiovascular Complications in People With or Without Type 2 Diabetes: The Fremantle Diabetes Study. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	10
106	Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	3
105	Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia. *Diabetes Technology and Therapeutics*, **2020**, 22, 367-373	8.1	8
104	A comparison of obesity indices in relation to mortality in type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia*, **2020**, 63, 528-536	10.3	6
103	Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Care*, **2020**, 43, 3034-3041	14.6	3
102	PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
101	Complementary and alternative medicine beliefs in type 2 diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Research and Clinical Practice*, **2020**, 166, 108311	7.4	1
100	Complementary medicine use and its cost in Australians with type 2 diabetes: the Fremantle Diabetes Study Phase II. *Internal Medicine Journal*, **2020**, 50, 944-950	1.6	3
99	Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. *Cardiovascular Diabetology*, **2020**, 19, 43	8.7	6
98	Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II. *Journal of Diabetes and Its Complications*, **2019**, 33, 107406	3.2	8
97	Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102-109. *Diabetes Care*, **2019**, 42, e101	14.6	
96	Subjective memory complaints are not increased in type 2 diabetes: A matched cohort study. *Journal of Diabetes and Its Complications*, **2019**, 33, 424-426	3.2	2
95	The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?. *Journal of Diabetes and Its Complications*, **2019**, 33, 427-433	3.2	
94	Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study. *Acta Diabetologica*, **2019**, 56, 767-776	3.9	6
93	Spray on skin for diabetic foot ulcers: an open label randomised controlled trial. *Journal of Foot and Ankle Research*, **2019**, 12, 52	3.2	1
92	Incidence, Risk Factors, and Outcomes of Intra-Abdominal Hypertension in Critically Ill Patients-A Prospective Multicenter Study (IROI Study). *Critical Care Medicine*, **2019**, 47, 535-542	1.4	72

91	A systematic review of risk factors for cataract in type 2 diabetes. *Diabetes/Metabolism Research and Reviews*, **2019**, 35, e3073	7.5	29
90	Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Care*, **2019**, 42, 288-296	14.6	5
89	Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I. *Diabetes Care*, **2019**, 42, 102-109	14.6	6
88	Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 648-657	6.7	3
87	Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study. *Diabetic Medicine*, **2018**, 35, 903-910	3.5	6
86	Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. *Internal Medicine Journal*, **2018**, 48, 1215-1221	1.6	
85	Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. *Journal of Diabetes and Its Complications*, **2018**, 32, 400-405	3.2	8
84	Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II. *Internal Medicine Journal*, **2018**, 48, 803-809	1.6	19
83	Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2852-2859	6.7	7
82	Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. *BMJ Open*, **2018**, 8, e020677	3	12
81	The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Research and Clinical Practice*, **2018**, 142, 294-302	7.4	5
80	The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II. *PLoS ONE*, **2018**, 13, e0194417	3.7	2
79	A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3531-3539	5.6	14
78	The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study. *Diabetes Research and Clinical Practice*, **2018**, 143, 62-70	7.4	5
77	Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: The Fremantle diabetes study. *Journal of Diabetes and Its Complications*, **2017**, 31, 945-947	3.2	4
76	A population-based study of the association between dysglycaemia and hearing loss in middle age. *Diabetic Medicine*, **2017**, 34, 683-690	3.5	8
75	Plasma Amyloid-Peptides in Type 2 Diabetes: A Matched Case-Control Study. *Journal of Alzheimer's Disease*, **2017**, 56, 1127-1133	4.3	8
74	Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis. *Journal of Diabetes and Its Complications*, **2017**, 31, 1169-1174	3.2	18

73	Circulating osteocalcin is unrelated to glucose homoeostasis in adults with type 1 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 948-951	3.2	5
72	Depression symptoms are persistent in Type 2 diabetes: risk factors and outcomes of 5-year depression trajectories using latent class growth analysis. *Diabetic Medicine*, **2017**, 34, 1108-1115	3.5	10
71	Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2985-2993	5.6	12
70	The Structured Interview for Insight and Judgment in Dementia: Development and validation of a new instrument to assess awareness in patients with dementia. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 7, 24-32	5.2	8
69	Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II. *Internal Medicine Journal*, **2017**, 47, 1206-1210	1.6	2
68	Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study. *Diabetes Research and Clinical Practice*, **2017**, 134, 153-160	7.4	12
67	The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II. *Medical Journal of Australia*, **2017**, 207, 344-347	4	11
66	Cost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children. *Malaria Journal*, **2017**, 16, 438	3.6	1
65	Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Care*, **2017**, 40, 1548-1555	14.6	39
64	Re: Subclinical thyroid dysfunction and mortality in type 2 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 1474	3.2	
63	Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I. *Diabetologia*, **2017**, 60, 89-97	10.3	25
62	Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 551-559	5.6	6
61	Successful Withdrawal of Insulin Therapy After Post-Treatment Clearance of Hepatitis C Virus in a Man with Type 2 Diabetes. *American Journal of Case Reports*, **2017**, 18, 414-417	1.3	3
60	Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Research and Clinical Practice*, **2016**, 122, 190-197	7.4	32
59	Comorbid Anxiety and Depression and Their Impact on Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Depression and Anxiety*, **2016**, 33, 960-966	8.4	21
58	Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes, Obesity and Metabolism*, **2016**, 18, 598-606	6.7	11
57	Lifetime depression history and depression risk in type 2 diabetes: A case-control study. *Journal of Diabetes and Its Complications*, **2016**, 30, 38-42	3.2	13
56	Changes in characteristics and management of Asian and Anglo-Celts with type 2 diabetes over a 15-year period in an urban Australian community: The Fremantle Diabetes Study. *Journal of Diabetes*, **2016**, 8, 139-47	3.8	5

55	Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes, Obesity and Metabolism*, **2016**, 18, 1143-1146	6.7	4
54	Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: the Fremantle Diabetes Study Phase II. *Clinical Endocrinology*, **2016**, 85, 444-52	3.4	12
53	A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy. *Journal of Stroke and Cerebrovascular Diseases*, **2016**, 25, 1119-1127	2.8	8
52	Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study. *Cardiovascular Diabetology*, **2016**, 15, 143	8.7	7
51	Re: Essential service standards for equitable national cardiovascular care for Aboriginal and Torres Strait Islander people. *Heart Lung and Circulation*, **2015**, 24, 626	1.8	1
50	Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes. *Diabetes Care*, **2015**, 38, 1274-80	14.6	41
49	Temporal changes in the prevalence and associates of foot ulceration in type 2 diabetes: the Fremantle Diabetes Study. *Journal of Diabetes and Its Complications*, **2015**, 29, 356-61	3.2	15
48	A comparison of two methods of foot health education: the Fremantle Diabetes Study Phase II. *Primary Care Diabetes*, **2015**, 9, 155-62	2.4	20
47	Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. *Malaria Journal*, **2015**, 14, 121	3.6	6
46	Fear of falling is common in patients with type 2 diabetes and is associated with increased risk of falls. *Age and Ageing*, **2015**, 44, 687-90	3	30
45	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 Australian cohorts. *International Journal of Cancer*, **2015**, 137, 1699-708	7.5	35
44	The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?. *Diabetes and Metabolism*, **2015**, 41, 463-9	5.4	22
43	Prevalence, risk factors and sequelae of Staphylococcus aureus carriage in diabetes: the Fremantle Diabetes Study Phase II. *Journal of Diabetes and Its Complications*, **2015**, 29, 1092-7	3.2	17
42	The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study. *Journal of Diabetes and Its Complications*, **2015**, 29, 1320-2	3.2	1
41	Apathy in older patients with type 2 diabetes. *American Journal of Geriatric Psychiatry*, **2015**, 23, 615-21	6.5	17
40	Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study. *Cardiovascular Diabetology*, **2015**, 14, 152	8.7	26
39	Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study. *Internal Medicine Journal*, **2015**, 45, 976-80	1.6	8
38	Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study Phase II. *Diabetes Research and Clinical Practice*, **2015**, 107, 384-91	7.4	13

37	A longitudinal study of foot ulceration and its risk factors in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Research and Clinical Practice*, **2014**, 106, 42-9	7.4	17
36	Diagnostic criteria for depression in type 2 diabetes: a data-driven approach. *PLoS ONE*, **2014**, 9, e112049	3.7	8
35	Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle Diabetes Study. *Journal of Alzheimer's Disease*, **2014**, 42 Suppl 3, S63-70	4.3	25
34	Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial. *PLoS Medicine*, **2014**, 11, e1001773	11.6	26
33	Clinical features and outcome in children with severe Plasmodium falciparum malaria: a meta-analysis. *PLoS ONE*, **2014**, 9, e86737	3.7	21
32	A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. *BMC Medical Genetics*, **2013**, 14, 15	2.1	56
31	Determinants and costs of community nursing in patients with type 2 diabetes from a community-based observational study: the Fremantle Diabetes Study. *International Journal of Nursing Studies*, **2013**, 50, 1166-71	5.8	3
30	Cohort profile: the Fremantle Diabetes Study. *International Journal of Epidemiology*, **2013**, 42, 412-21	7.8	88
29	Clinical impact of the temporal relationship between depression and type 2 diabetes: the Fremantle diabetes study phase II. *PLoS ONE*, **2013**, 8, e81254	3.7	18
28	Continuing disparities in cardiovascular risk factors and complications between aboriginal and Anglo-Celt Australians with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care*, **2012**, 35, 2005-11	14.6	36
27	A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. *International Journal of Pharmacy Practice*, **2011**, 10, 85-89	1.7	35
26	Economic impact of moderate weight loss in patients with Type 2 diabetes: the Fremantle Diabetes Study. *Diabetic Medicine*, **2011**, 28, 1131-5	3.5	20
25	Angiotensin-converting enzyme insertion/deletion polymorphism and severe hypoglycemia complicating type 2 diabetes: the Fremantle Diabetes Study. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E696-700	5.6	9
24	Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. *Bulletin of the World Health Organization*, **2011**, 89, 211-20	8.2	16
23	An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. *Internal Medicine Journal*, **2010**, 40, 286-92	1.6	45
22	Apolipoprotein E genotype and mortality in Southern European and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. *European Journal of Endocrinology*, **2010**, 163, 559-64	6.5	4
21	Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA. *Evidence-Based Medicine*, **2010**, 15, 40-1		1
20	Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. *Diabetes Research and Clinical Practice*, **2010**, 90, e75-8	7.4	6

19	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. *Medical Journal of Australia*, **2009**, 190, 180-4	4	21
18	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. *Medical Journal of Australia*, **2009**, 190, 180-184	4	39
17	Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia*, **2008**, 51, 562-6	10.3	125
16	Characteristics and outcome of type 2 diabetes in urban Aboriginal people: the Fremantle Diabetes Study. *Internal Medicine Journal*, **2007**, 37, 59-63	1.6	27
15	Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. *Diabetologia*, **2007**, 50, 510-5	10.3	64
14	Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia*, **2006**, 49, 2634-41	10.3	112
13	Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care*, **2006**, 29, 575-80	14.6	156
12	Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. *Diabetes Care*, **2006**, 29, 1764-70	14.6	70
11	Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. *Medical Journal of Australia*, **2006**, 184, 325-8	4	51
10	The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. *Internal Medicine Journal*, **2006**, 36, 155-61	1.6	20
9	A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia*, **2005**, 48, 2532-9	10.3	101
8	Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care*, **2005**, 28, 2441-7	14.6	97
7	Determinants of diabetes-attributable non-blood glucose-lowering medication costs in type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care*, **2005**, 28, 329-36	14.6	23
6	Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Care*, **2004**, 27, 752-7	14.6	202
5	Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. *Diabetologia*, **2004**, 47, 395-399	10.3	51
4	Prevalence and Predictors of Complementary Medicine Usage in Diabetes: Fremantle Diabetes Study. *Journal of Pharmacy Practice and Research*, **2003**, 33, 260-264	0.7	23
3	The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. *British Journal of Clinical Pharmacology*, **2001**, 52, 137-44	3.8	47
2	Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study. *Diabetes Research and Clinical Practice*, **2001**, 52, 63-71	7.4	60

1	Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. *Diabetic Medicine*, **2000**, 17, 667-74	3.5	101